ClinicalTrials.gg

Program

SSGJ-706

A development code. Also written as “SSGJ-706+Bevacizumab+XELOX”, “SSGJ-706+AG” and “SSGJ-706+TP”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by 3SBio.

Furthest: phase 2, since Sep 1, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio43 open or runningphase 2since Sep 1, 2025Jul 29, 2024Dec 2026phase 2 · NCT07233850

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2024First study: phase 1 study in Advanced Solid Tumors PatientsFirst studyNCT06533605 · 60 enrolled
  2. Sep 1, 2025Phase 2 study in First-line Advanced NSCLC PatientsNCT07171606 · 240 planned · China
  3. Nov 14, 2025Phase 2 study in Colorectal NeoplasmsNCT07233850 · 300 planned · China
  4. Sep 20, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984 · 220 planned

Ahead

  1. Dec 2026Primary completion: phase 2 study in Colorectal NeoplasmsNCT07233850
  2. Nov 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07874984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07874984Carcinoma, Non-Small-Cell Lung2Not yet recruitingNov 2027220
NCT07233850Colorectal Neoplasms · China2Not yet recruitingDec 2026300
NCT07171606First-line Advanced NSCLC Patients · China2RecruitingAug 31, 2026240
NCT06533605Advanced Solid Tumors Patients1UNKNOWNJul 30, 202560

How it is read

Names in the registry

  • “SSGJ-706”, 3 entries
  • “SSGJ-706+Bevacizumab+XELOX”, 1 entry
  • “SSGJ-706+AG”, 1 entry
  • “SSGJ-706+TP”, 1 entry

Codes read as this program: SSGJ706.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
SSGJ-706 (3SBio): development program | ClinicalTrials.gg